|Articles|June 27, 2023
Opioid Reformulation for Abuse Deterrence - Filed as a CMC Supplement in Less Than a Year
Author(s)Societal CDMO
It is no secret that Opioid abuse is an ongoing public health emergency. Societal™’s client stood at an impasse in pursuit of providing pain relief to patients, while following the recommendation of the FDA to reformulate the product for abuse deterrence.
Related Content
Sponsored Content
Trending on Pharmaceutical Technology
1
The Implications of Isatuximab-irfc’s FDA Approval for Multiple Myeloma
2
The FDA Moves to Modernize Drug Manufacturing Registration
3
PharmTech Weekly Roundup–July 10, 2026
4
What the Ocrelizumab Deal Does for the Multiple Sclerosis Biosimilar Pipeline
5